 |
|
Hypertrophic Cardiomyopathy
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: We feel compelled to object to much of the content of the article on hypertrophic cardiomyopathy (HCM) by Dr Fananapazir,1 published as a Grand Rounds from the National Institutes of Health.
First, the ventricular septal myotomy-myectomy operation is at present the treatment of choice for patients with severe outflow obstruction and disabling symptoms refractory to drug treatment. At experienced centers, surgery has proved (for more than 40 years) to be highly successful in relieving obstruction and symptoms on a long-term basis and has an operative mortality that is now low ( 1%-2%).2 Indeed, some surgeons have reported virtually no operative mortality in more recent years.3 Therefore, the statement by Fananapazir that "these are major operations with significant mortality and morbidity" is misleading. Readers should be aware that surgery remains an important option for severely symptomatic patients with obstructive HCM.
Second, the significance of dual-chamber pacing in the . . . [Full Text of this Article]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Advances in Molecular Genetics and Management of Hypertrophic Cardiomyopathy
Lameh Fananapazir
JAMA. 1999;281(18):1746-1752.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Two Functionally Identical Modular Enhancers in Drosophila Troponin T Gene Establish the Correct Protein Levels in Different Muscle Types
Mas et al.
Mol. Biol. Cell 2004;15:1931-1945.
ABSTRACT
| FULL TEXT
The need for European Registries in inherited cardiomyopathies
Arbustini et al.
Eur Heart J 2002;23:1972-1974.
|
